Compare GSK plc (GSK) vs S&P500 ETF (SPY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs S&P500 ETF — how do they compare? GSK plc trades at $46.6 (market cap $91.88B), while S&P500 ETF trades at $778.04 (market cap $821.54B). The key difference: S&P500 ETF is far larger — about 8.9× GSK plc's market cap, and GSK plc pays a 3.9% dividend while S&P500 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and S&P500 ETF for 205 Days on average.
| GSK | SPY | |
|---|---|---|
Market Cap | $91.88B | $821.54B |
Volume | 7,730,529 | 40,070,358 |
Sector | Health | — |
52-Week High | $61.18 | $779.14 |
52-Week Low | $43.24 | $631.99 |
Typical Hold Time | 93 Days | 205 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
SPY, tracking the S&P 500, trades at $775.78, down 0.19% on the day amid a mixed technical backdrop with a bullish moving average signal but neutral oscillators. The ETF shows no available fundamental ratios in this snapshot, and a dividend of $1.89 is scheduled for payment in October 2026. Recent news highlights market volatility, with articles discussing valuation concerns and sector rotations.
The outlook for SPY hinges on broader market trends, with technical support near $771 offering a cushion. Risks include potential earnings growth slowdowns and macroeconomic pressures, but the bullish moving average alignment suggests underlying strength for long-term investors focused on U.S. equity exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About S&P500 ETF
The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →
